Tribunal rules in favor of appellant, emphasizing statutory distinctions in duty liability determination

The Tribunal determined that the third party, SPPL, was the manufacturer under the Central Excise Act, absolving the appellant of liability for duty payment. The Loan License Agreement was deemed irrelevant, focusing instead on the actual manufacturing process and responsibilities under the Drugs and Cosmetics Act, 1940. Emphasizing the distinction between the two statutes, the Tribunal relied on the Supreme Court's precedent to rule in favor of the appellant and associated individuals, highlighting the necessity of evidence in determining liability under different statutes.

---

---

Issues:
Manufacture of drugs by a third party on behalf of the appellant, determination of the manufacturer under Central Excise Act, 1944, liability for duty payment, relevance of Loan License Agreement, clandestine removal of goods, responsibility of job worker, application of Drugs and Cosmetics Act, 1940, interpretation of "manufacture" under Central Excise Act, 1944, liability under different statutes, applicability of Supreme Court's ruling in CCE, Goa Vs Cosme Farma Laboratories Ltd.

Analysis:

1. The appellant sent raw materials to a third party, SPPL, for manufacturing drugs. The appellant argued that SPPL had the necessary drug license and capabilities to manufacture the goods on its behalf. The Department alleged a clandestine removal of goods and attempted to hold the appellant liable for duty payment, treating SPPL as a job worker.

2. The central issue was to determine the manufacturer under the Central Excise Act, 1944. The Tribunal clarified that the Loan License Agreement was irrelevant to this determination. The focus was on Section 3 of the Central Excise Act, not the quality of the drugs or the terms of the agreement. Mere supply of raw materials did not change the manufacturer or job worker status.

3. The Tribunal emphasized that SPPL, being a drug license holder with manufacturing capabilities, was responsible for compliance with the Drugs and Cosmetics Act, 1940. The Department failed to investigate the manufacturing process or the role of the appellant's representatives. SPPL's adherence to quality control did not alter its manufacturing status for the appellant.

4. The judgment highlighted the distinction between the Drugs and Cosmetics Act, 1940, and the Central Excise Act, 1944. While the former regulates drug manufacturing, the latter concerns excisable goods. The factual circumstances led to SPPL being considered the manufacturer under the Central Excise Act, absolving the appellant of liability.

5. Citing the Supreme Court's ruling in CCE, Goa Vs Cosme Farma Laboratories Ltd., the Tribunal allowed the appeal, stating that in the absence of evidence to the contrary, the appellant could not be deemed the manufacturer. Consequently, the appeals of other individuals associated with the appellant were also allowed.

6. The judgment concluded by allowing all appeals, aligning with the Supreme Court's precedent and emphasizing the importance of evidence in determining liability under different statutes.

---